School lessons could be key to beating cervical cancer in Low-Income nations

NCT ID NCT07784283

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This large school-based study in Cambodia and Kenya tests whether adding age-appropriate lessons about HPV, the HPV vaccine, and cervical cancer to existing health classes can increase vaccination coverage and improve students' knowledge and attitudes. About 9,000 students in grades 3-9 will participate, with some schools receiving the extra education and others continuing their usual curriculum. Researchers will compare vaccination rates and survey responses between the two groups, and also interview teachers, caregivers, and health workers to see if the program is practical and affordable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Integrated HPV education delivered by trained teachers in school health classes
What this could lead to
If effective, this low-cost, school-based education model could be scaled to boost HPV vaccination rates and reduce cervical cancer risk in low-resource settings.
What could go wrong
The trial's non-randomized design and reliance on school records may limit the strength of conclusions. Results may not generalize beyond these countries or grade levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9,054 people

The number who actually took part.

Started

Dec 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Student educational intervention population: Girls and boys enrolled in the country-specific target grades at participating schools (Cambodia: Grades 3-5; Kenya: Grades 4-8 during intervention implementation). In Kenya, the targeted cohorts progressed to Grades 5-9 by the January 2026 endline. Student eligibility for the educational intervention was primarily grade-based rather than based on a single numerical age restriction. * Student KAP questionnaire participants: Students in the relevant study grades at selected KAP schools who met country-specific consent/assent and literacy requirements. KAP recruitment used independent repeated cross-sectional samples at baseline and endline; individual students were not longitudinally linked across rounds. * HPV vaccination coverage population: Girls eligible for routine HPV vaccination in participating schools according to country-specific national vaccination policy (9-year-old girls in Cambodia; girls aged 10-14 years in Kenya). These age criteria applied to the vaccination coverage outcome and did not define eligibility for exposure to the educational curriculum. * Caregivers: Age 18 years or older, caring for an age/grade-eligible student at a participating school, able to provide informed consent, and able to communicate in the applicable study language(s). * Teachers: Age 18 years or older, involved in relevant school health/SRH education, able to provide informed consent, and able to communicate in the applicable study language(s). Teacher qualitative feasibility interviews were conducted in intervention settings. * Healthcare workers: Age 18 years or older, working in a health facility serving participating-school catchment areas, involved in HPV immunization and/or education, able to provide informed consent, and able to communicate in the applicable study language(s). Healthcare-worker qualitative feasibility interviews were conducted in intervention settings. Exclusion Criteria: * Students outside the applicable study grades or not attending participating schools; for the KAP questionnaire, students without the required consent/assent or who did not meet country-specific literacy requirements. * Caregivers, teachers, or healthcare workers younger than 18 years, unable to provide informed consent, unable to communicate in the applicable study language(s), or not meeting the relevant role-based eligibility criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer prevention are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Participating primary schools, Kampong Cham Province

    Kampong Cham, Kampong Cham, Cambodia

  • Participating primary schools, Kilifi County

    Kilifi, Kilifi County, Kenya

  • Participating primary schools, Kratie Province

    Kratie, Kratie, Cambodia

  • Participating primary schools, Migori County

    Migori, Migori County, Kenya

  • Participating primary schools, Nairobi County

    Nairobi, Nairobi County, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.